Trial reportBMC oral health2026
Effect of sodium hypochlorite and hyaluronic acid in subgingival re-instrumentation - a randomized clinical trial.
Trial report in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdjunctive antimicrobials may improve the outcome of subgingival instrumentation, but due to the lack of evidence no antimicrobial agent is recommended for subgingival re-instrumentation (SRI). The aim of this study was to clinically, immunologically and microbiologically evaluate the potential additional effects of amino-acid sodium hypochlorite (AA-NaOCl) and cross-linked hyaluronic acid (xHA) to SRI at 3 and 6 months.
methodsAt the time point of reevaluation during systematic periodontal therapy, eligible patients were allocated to either control group receiving SRI of residual pockets, or test group with the adjunctive AA-NaOCl and xHA. Per patient 2 study sites were selected and clinical periodontal parameters (PD, CAL, BOP, and pocket closure), immunological biomarkers and 8 major periopathobionts were analyzed at baseline, after 3 and 6 months. Detection of IL-1β and MMP-8 was carried out using ELISA, the abundance of the periopathobionts by qPCR.
resultsImprovements in the clinical parameters were demonstrated in all 42 included patients. In the test group an additional PD reduction by 0.50 mm (1.38, 95% CI range: 1.11-1.65 vs. 0.88, 95% CI range: 0.62-1.14; p = 0.008) and CAL gain by 0.57 mm (1.07, 95% CI range: 0.70-1.44 vs. 0.50, 95% CI range: 0.24-0.76; p = 0.017) was found compared to the control group. The percentage of residual pockets decreased by 88.1% (n = 37) in the test, and 38.1% (n = 16) in the control group. There was no significant change in the immunological parameters. The abundance of 5 periopathobionts significantly decreased in the test group.
conclusionsThe adjunctive application of AA-NaOCl and xHA significantly improved the clinical and microbiological outcome 3 and 6 months after SRI.
trial registrationThis trial was registered in the German Clinical Trials Register (ID: DRKS00017415 at 03/06/2019).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.